Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Hamill, P.A.; McIlkenny, P.; Opong, K.K. (2013)
Publisher: Elsevier
Languages: English
Types: Article

Classified by OpenAIRE into

mesheuropmc: health care economics and organizations
This paper examines shareholder wealth effects surrounding applications to, and approvals by, the United States Food and Drug Administration (FDA) for firms listed on the New York (NYSE) and London (LSE) stock exchanges. Applications to the FDA for drug approvals significantly increase shareholder wealth for NYSE firms only. The increase is driven by applications for enhancements to existing drugs, with the market anticipating the application, thus suggesting information leakage. FDA approvals also significantly increase shareholder wealth in both markets. However, there is no evidence of information leakage and the significant post-event abnormal returns support the attention-grabbing hypothesis. Enhanced drug approvals are value-relevant for both markets, which highlights the contribution of real-options to firm value.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Akerlof, G. A. (1970). The market for "lemons": quality uncertainty and the market mechanism, The Quarterly Journal of Economics, 84(3), 488-500.
    • Amir, E., & Lev, B. (1996). The value-relevance of nonfinancial information: a discussion.
    • Journal of Accounting and Economics, 22, 1-3, 31-42 Botosan, C., & Plumlee, M. (2001). Estimating expected cost of equity capital: a theorybased approach. Working paper, University of Utah, November. Available at SSRN: http://ssrn.com/abstract=279309.
    • Brown, S.J., & Warner, J.B. (1985). Using Daily Stock Returns, Journal of Financial Economics, 14, 3-31.
    • Busby, J.S. & Pitts, C.G., (1997). Real options in practice: an explanatory survey of how finance officers deal with flexibility in capital appraisal. Management Accounting Research, 8, 169-184.
    • Corrado, C. J. (1989). A nonparametric test for abnormal security-price performance in event studies. Journal of Financial Economics, 23, 385-395.
    • Dedman, E., Lin, W.J., Prakash, A.J., & Chang, C.H. (2008). Voluntary disclosure and its impact on share prices: evidence from the UK biotechnology sector, Journal of Accounting and Public Policy, 27(3), 195-216.
    • DiMasi, J. (1995). Success rates for new drugs entering clinical testing in the United States. Clinical Pharmacology and Therapeutics, 58, 1-14.
    • DiMasi, J., Hansen, R., & Grabowski, H. (2003). The price of innovation: new estimates of drug development costs, Journal of Health Economics, 22, 151-185.
    • Dranove, D. & Olsen, C. (1994). The economic side effect of dangerous drug announcements, Journal of Law and Economics, 37, 323-348.
    • Dye, R.A. (2001). An evaluation of “essays on disclosure” and the disclosure literature in accounting, Journal of Accounting and Economics, 32(1-3), 181-235.
    • Eccles, R.G., Herz, R.H., Keegan, E.M., & Phillips, D.M.H. (2001). The value reporting revolution: moving beyond the earnings game, New York: John Wiley & Sons, Inc.
    • Ely, K., Simko, P.J., & Thomas, L.G. (2003). The usefulness of biotechnology firms' drug development status in the evaluation of research and development costs, Journal of Accounting, Auditing & Finance, 18(1), 163-196.
    • Espinosa, M., Gietzmann, M., & Raonic, I. (2009) US institutional investors' response to the news flow of intangibles intensive European stocks: a study of European biotech and pharma stocks, European Accounting Review, 18(1), 63-92.
    • Fama, E. & French, K. R. (1993). Common risk factors in the returns on stocks and bonds. Journal of Financial Economics, 33, 3-56.
    • Fama, E. & French, K. R. (1996). Multifactor explanations of asset pricing anomalies. Journal of Finance, 51, 55-84.
    • Flavin, T. J. (2004). The effect of the Euro on country versus industry portfolio diversification, Journal of International Money and Finance, 23, 1137-1158.
    • Gelb, D. S., & Zarowin, P. (2002). Corporate disclosure policy and the informativeness of stock prices, Review of Accounting Studies, 7, 33-52.
    • Hail, L., Leuz, C., & Wysocki, P. (2009). Global accounting convergence and the potential adoption of IFRS by the United States: an analysis of economic and policy factors. Working paper, The Whartson School, University of Pennsylvania.
    • Hamill, P.A., McGregor, P., & Opong, K.K. (2002). Equity option listing: a comparison of event study methodologies, Journal of Empirical Finance, 9, 91-108.
    • Hartman, M., & Hassan, A. (2006). Application of real options analysis for pharmaceutical R&D project valuation - Empirical results from a survey. Research Policy, 35, 343-354.
    • Healy, P. M., Hutton, A., & Palepu, K. G. (1999). Stock performance and intermediation changes surrounding sustained increases in disclosure, Contemporary Accounting Research, 16(3), 485-520.
    • Healy, P. M., & Palepu, K. G. (2001). Information asymmetry, corporate disclosure, and the capital markets: a review of the empirical disclosure literature, Journal of Accounting and Economics, 31(3), 405-440.
    • Hingorani, A., Shastri, K.A., & Shastri, K. (1994). Product regulation and stock prices: the case of the food and drug administration, Journal of the Economics of Business, 1, 163- 177.
    • Howell, S.D., & Jägle, A.J. (1997). Laboratory evidence on how managers intuitively value real growth options. Journal of Business Finance and Accounting, 24, 915-935.
    • MacKinlay, A.C. (1997) Event Studies in Economics and Finance, Journal of Economic Literature, 35, 13-39.
    • McNarama, P., & Baden-Fuller, C. (2007). Shareholder returns and the explorationexploitation dilemma: R&D announcements by biotechnology firms, Research Policy, 36, 548-565.
    • Merton, R. C. (1998). Applications of option-pricing theory: Twenty-five year later. American Economic Review, (June) 323-349.
    • Odean, T. (1999). Do investors trade too much? American Economic Review, 89, 1279-12.
    • Pfeiffer, T., & Schneider, G. (2010). Capital budgeting, information timing, and the value of abandonment options. Management Accounting Research, 21, 238-258.
    • Phylaktis, K., & Xia, L. (2006). Sources of firms' industry and country effects in emerging markets, Journal of International Money and Finance, 25, 459-475.
    • Remer, S., Ang, S.H., & Baden-Fuller, C., (2001). Dealing with uncertainties in the biotechnology industry: the use of real options reasoning. Journal of Commercial Biotechnology, 8, 95-105.
    • Rothaermel, F.T. (2001a). Incumbent's advantage through exploiting complementary assets via interfirm cooperation, Strategic Management Journal, 22, (6-7), 687-699.
    • Table 2 Shareholder wealth effects: FDA Application Announcements Event Days Abnormal Returns t-statistic Robust (%) p-values Panel A: NYSE Listed [-21, -1] 1.22 1.60 [-10, -1] 1.73 1.96 * [-5, -1] 1.24 2.03 ** [-5, 0] 1.52 3.70 ** 0 0.28 1.66 1 -0.18 -1.08 2 0.01 0.06 [1, 2] -0.16 -0.49 [1, 21] 0.47 0.60 [2, 21] 0.65 0.51 [3, 21] 0.64 0.51
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article